Information Provided By:
Fly News Breaks for August 10, 2017
Aug 10, 2017 | 08:21 EDT
Roth Capital analyst Michael Higgins downgraded Cempra to Neutral from Buy after the company announced plans to merge with Melinta Therapeutics in an all-stock transaction. The analyst also lowered his price target on Cempra's shares to $4 from $8.
News For CEMP From the Last 2 Days
There are no results for your query CEMP